Forum ODDO BHF
January 9-10, 2020 – Lyon, France
January 13-16, 2020 – San Francisco, CA, USA
January 15-17, 2020 – Toulouse, France
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne